Excessive use of reliever inhalers for asthma is linked to a significantly increased risk of dying from the disease, a new study revealed today. Researchers found that over-use of short acting ...

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy. Investigator sites are essential for ...

Despite these and other positive pieces of evidence provided by publications in the last decade, inhaled CS have not been considered effective in treating asthma exacerbations. Different state-of ...

As with rescue inhalers, there are combination inhalers that combine LABAs with LAMAs ... This includes recommendations by the FDA that LABAs ONLY be used in combination with ICS for asthma. Here is ...

Recent research reveals that anti-inflammatory inhalers not only cut the risk of severe asthma complications but also offer modest improvements in symptom control compared to traditional ...

Current albuterol rescue inhalers alleviate acute symptoms, but do not treat the underlying inflammation in asthma.” He continued: “The approval of Airsupra means that, for the first time ...

However, it's safer to use a rescue inhaler than wait to see if symptoms will improve without it. Low-intensity activities (e.g., walking, hiking) or sports with short bursts of exertion (e.g., ...

Clinical evidence shows that inhaled CS present early benefits (within 1-2 h) for the treatment of children and adults with acute asthma. Patients (children and adults) who received inhaled CS ...

Details of the study were presented in a session at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting (ACAAI 2024) in Boston. Reliever inhalers, including ...

Albuterol/budesonide, previously known as PT027, is a short-acting beta2-agonist (SABA) and inhaled corticosteroid (ICS) asthma rescue therapy approved under the brand name Airsupra ®. The product is ...